Influenza
Conditions
Interventions
Group 1:Receive a single probiotic CCFM1026 supplement
Group 2:A compound probiotic (CCFM1026+GL-104+MP108) was administered
Group 3:Take placebo
Sponsors
Affiliated Hospital of Jiangnan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years. 2. The patient was clinically diagnosed with influenza virus infection. 3. Can cooperate with the collection of experimental specimens and regular callback. 4. Patient or family member has signed subject consent form.
Exclusion criteria
Exclusion criteria: 1. The patient was first diagnosed as having other serious diseases combined with influenza. 2. Congenital intestinal abnormalities, such as Hirschsprung's disease or intestinalatresia, are appraised by physicians as not appropriate to be added to this clinical trial. 3. Other gastrointestinal diseases with symptoms of intestinal inflammation and increased permeability. 4. Patients who have taken immunosuppressive drugs, steroids, various antibiotics and Tcell inhibitor ointment within 4 weeks. 5. The patient has consumed probiotic-related products (powder, yogurt, yogurt, or other fermented foods) on a continuous basis (for five or more consecutive days) within the last 1 month. 6. Use nasal spray five or more days a week, systemic steroids, testosterone, or high-dose anti-inflammatory drugs (e.g., aspirin greater than 600 mg/day) for those who have participated in other clinical trials and are on trial drugs within the last 1 month. 7. No probiotics were taken for more than 10 days during the trial. 8. Patients who plan to change their rhinitis medication in the short term. 9. Others who were assessed by physicians as unfit to enter the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| height;fecal NGS analysis;IgG;IL-6;IL-8;IgA;weight;body mass index;blood pressure;temperature;pulse; | — |
Countries
China
Contacts
Public ContactLu Wenwei
Outcome results
None listed